Researchers screening roughly 400 transcription factors found that disabling a single protein, NFIL3, allowed CAR T-cells to sustain their tumor-killing activity longer in preclinical models. The ...

Researchers at Columbia University’s Sadelain lab and University Hospital Tubingen used CRISPR gene editing to knock out the transcription factor NFIL3 in engineered CAR T cells, and the modified ...

New preclinical and translational findings position DNase I as a potentially transformative adjunct therapy for CAR-T ...

T cells are crucial components of our immune system, serving as critical protectors against infection and disease. But there are limits to their defensive capabilities. T cells are not inexhaustible ...

A research team from the Johns Hopkins Kimmel Cancer Center, its Bloomberg~Kimmel Institute for Cancer Immunotherapy and the Johns Hopkins Bloomberg School of Public Health has discovered how the ...

UCLA researchers gave T cells a protected supply of sugar, allowing them to attack solid tumors more effectively.

Metabolism guides the activation states of regulatory T cells, the immune cells that prevent inappropriate activation of the immune system. St. Jude Children's Research Hospital scientists recently ...

CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...

Chimeric antigen receptor T cell (CAR-T) therapies have revolutionized treatment for various blood cancers. When traditional treatments fail, CAR-T therapies provide a second highly effective option.

A research team from the Johns Hopkins Kimmel Cancer Center, its Bloomberg~Kimmel Institute for Cancer Immunotherapy and the Johns Hopkins Bloomberg School of Public Health have discovered how the ...